Article
Optical complications were substantial glare in about 20% of patients, halos in 30%, and problems with night driving in 20%.
Melt Pharmaceuticals reports positive Phase 3 topline efficacy results for MELT-300
(EyePod) From idea to impact: Navigating ophthalmic innovation
Study explores the true costs of treating pediatric cataracts
EyePod: Integrating cutting-edge pipeline devices for enhanced cataract surgery
Study: Aromatherapy decreased postoperative patient anxiety and pain associated with oculoplastic surgery
Raising cataract surgery procedure to an art and an experience